Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 14/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5815092 | 0.96 | PRKCI (0.43) | PRKCICHRM4GAAMAPTNPSR1 | |
| SCHEMBL5128775 | 0.94 | MAPT (0.47) | PRKCICHRM4GAAMAPTNPSR1 | |
| SCHEMBL7513678 | 0.91 | MAPT (0.44) | PRKCICHRM4GAAMAPTNPSR1 | |
| SCHEMBL7615852 | 0.91 | PRKCI (0.49) | PRKCI | |
| SCHEMBL5123014 | 0.91 | PRKCI (0.58) | PRKCICHRM4GAAMAPTNPSR1 | |
| SCHEMBL5128699 | 0.89 | MAPT (0.54) | CHRM4GAAMAPTNPSR1DYRK1A | |
| SCHEMBL5129890 | 0.86 | PRKCI (0.51) | PRKCI | |
| SCHEMBL7171668 | 0.86 | MAPT (0.51) | CHRM4GAAMAPTNPSR1DYRK1A | |
| SCHEMBL5121690 | 0.86 | CHRM4 (0.41) | CHRM4MAPTNPSR1CLK1CLK2 | |
| SCHEMBL5124992 | 0.85 | PRKCI (0.49) | PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | PRKCI 1513/4885CHRM4 4573/4885GAA 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.